Sfoglia per AUTORE
ADDEO A
Collezione AOU San Luigi di Orbassano

  

Items : 14

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. in International immunopharmacology / Int Immunopharmacol. 2022 Sep;110:108985. doi: 10.1016/j.intimp.2022.108985. Epub 2022 Jun 28.
2022
ASL Torino 4
AOU San Luigi di Orbassano

Pinato DJ; Bainbridge H; Hicks A; Chan S; Barone G; Escriu C; Signori A; McKenzie H; Addeo A; Cortellini A; Comins C; Cave J; Muthuramalingam S; Cantale O; Banna GL; Ottensmeier C; Gomes F;

International Survey on Frailty Assessment in Patients with Cancer. in The oncologist / Oncologist. 2022 Oct 1;27(10):e796-e803. doi: 10.1093/oncolo/oyac133.
2022
ASL Torino 4
AOU San Luigi di Orbassano

Garetto L; Maltese G; O'Carroll E; Musolino N; Bambury K; Battisti NML; Haydock MM; Cantale O; Banna GL; Addeo A; Gomes F;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Russano M; Porzio G; Tiseo M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Metro G; Spinelli GP; Passiglia F; Migliorino MR; Ricciardi S; Pecci F; Zoratto F; De Tursi M; Di Marino P; Mansueto G; Tuzi A; Gori S; Della Gravara L; Rastelli F; Chiari R; Macerelli M; Marchetti P; Gelibter A; Antonuzzo L; Berardi R; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AOU San Luigi di Orbassano
AO Ordine Mauriziano
AOU Novara

Russo A; Adamo V; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Ricciardi S; Landi L; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Filetti M; Zoratto F; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Gelibter A; Targato G; Signorelli D; De Toma A; Mazzoni F; et alii...

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. in Thoracic cancer / Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.
2021
AOU San Luigi di Orbassano

Donisi C; De Toma A; Landi L; Minuti G; Bordi P; Leonetti A; Nigro O; Cantini L; Russano M; Pensieri MV; Montrone M; Citarella F; Filetti M; Mansueto G; Zoratto F; Di Marino P; De Tursi M; Inno A; Gravara LD; Chiari R; Rastelli F; Follador A; Occhipinti MA; Gelibter A; Signorelli D; Di Noia V; Antonuzzo L; Rossi G; Sforza V; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cannita K; Porzio G; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Russo A; Adamo V; Metro G; Olmetto E; Tabbò F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Tuzi A; Bisonni R; Follador A; Siringo M; Gelibter A; Signorelli D; De Toma A; Garassino MC; Mazzoni F; Russano M; Citarella F; Filetti M; Zoratto F; Mansueto G; et alii...

2021
AOU San Luigi di Orbassano
ASL Città di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Bordi P; Tuzi A; Cantini L; Russano M; Citarella F; Santini D; Filetti M; Zoratto F; Mansueto G; Di Marino P; Grassadonia A; Michele T; Inno A; Della Gravara L; Rocco D; Chiari R; Rastelli F; Macerelli M; Marchetti P; Siringo M; et alii...

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Giusti R; Porzio G; Ficorella C; Petrelli F; Addeo A; De Toma A; Friedlaender A; Tabbò F; Ricciardi S; Della Gravara L; Guaitoli G; Landi L; Scodes S; Buti S; Nigro O; Ferrara MG; Targato G; Cantini L; Russano M; Citarella F; Pizzutilo P; Filetti M; Grossi F; Zoratto F; Mansueto G; De Tursi M; Di Marino P; Rocco D; Inno A; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Belderbos RA; De Filippis M; Dal Bello MG; Della Gravara L; Bertolini F; Baldessari C; Guaitoli G; Landi L; Antonuzzo L; Scodes S; Pettoruti L; Leonetti A; D'Argento E; Ferrara MG; Nigro O; Sforza V; Follador A; Torniai M; Cantini L; Russano M; Citarella F; Occhipinti MA; Sala L; Pizzutilo P; Catino A; Filetti M; Ghidini M; Tudini M; Santoni M; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Dal Bello MG; Della Gravara L; Baldessari C; Guaitoli G; Landi L; Scodes S; Antonuzzo L; Bordi P; Buti S; D'Argento E; Ferrara MG; Sforza V; Nigro O; Targato G; Cantini L; Torniai M; Marco R; Citarella F; Sala L; Pizzutilo P; Catino A; Filetti M; Rijavec E; Tudini M; Santoni M; Zoratto F; Mansueto G; De Tursi M; Gori S; et alii...

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. in Current oncology reports / Curr Oncol Rep. 2019 Nov 25;21(12):107. doi: 10.1007/s11912-019-0852-9.
2019
AOU San Luigi di Orbassano

Addeo A; Buffoni L; Banna GL; Friedlaender A;

Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156]. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2019 Jul;139:158. doi: 10.1016/j.critrevonc.2018.06.018. Epub 2018 Nov 2.
2019
AOU San Luigi di Orbassano

Buffoni L; Novello S; Robinson T; Tabbò F; Addeo A;

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Feb;122:150-156. doi: 10.1016/j.critrevonc.2017.12.015. Epub 2017 Dec 3
2018
AOU San Luigi di Orbassano

Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S;

Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2005 Feb;47(2):269-75. doi: 10.1016/j.lungcan.2004.06.019.
2005
AOU Città della Salute di Torino
AOU San Luigi di Orbassano

Dongiovanni D; Fissore C; Berruti A; Buffoni L; Addeo A; Barone C; Polimeni MA; Ottaviani D; Bertetto O; Dongiovanni V;

©2024 Tutti i diritti riservati. Biblioteca Virtuale per la Salute - Piemonte